Clustering of dosimetric profiles reveals distinct local control probabilities after SABR in oligometastatic head and neck cancer: insights from the OMET phase II trial quality assurance Process.

Date publication

décembre 2025

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi , Mr FALCOZ Antoine

Tous les auteurs :
Maury P, Sayous Y, Vernerey D, Sun XS, Bourhis J, Falcoz A, Thariat J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41352456

Résumé

Stereotactic ablative radiotherapy (SABR) is increasingly used in the management of oligometastatic disease. However, variability in SABR plans raises questions about their impact on local control at SABR-treated lesions (LC). We aimed to explore whether quantitative dosimetric parameters could predict LC in head and neck squamous cell carcinoma (HNSCC) patients in the OMET (GORTEC 2014-04) trial.

Mots clés

Clustering, Dosimetric predictors, Head and neck neoplasms, Local tumor control, Oligometastatic disease, Radiotherapy quality assurance, Stereotactic ablative radiotherapy (SABR)/ Stereotactic body radiotherapy (SBRT)

Référence

Radiother Oncol. 2025 12 4;214:111316